BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1075 related articles for article (PubMed ID: 9514454)

  • 21. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
    Cromwell WC; Ziajka PE
    Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
    Edwards JE; Moore RA
    BMC Fam Pract; 2003 Dec; 4():18. PubMed ID: 14969594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
    Steinhagen-Thiessen E
    Cardiology; 1994; 85(3-4):244-54. PubMed ID: 7987882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
    Bakker-Arkema RG; Nawrocki JW; Black DM
    Atherosclerosis; 2000 Mar; 149(1):123-9. PubMed ID: 10704623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients.
    Tamura A; Watanabe T; Nasu M
    Circ J; 2003 Oct; 67(10):816-20. PubMed ID: 14578611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of statins in hypertriglyceridemia.
    Stein EA; Lane M; Laskarzewski P
    Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
    Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
    Hilleman DE; Wurdeman RL; Lenz TL
    Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New statins and new doses of older statins.
    Stein EA
    Curr Atheroscler Rep; 2001 Jan; 3(1):14-8. PubMed ID: 11123843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
    Jorge PA; Almeida EA; Ozaki MR; Jorge M; Carneiro A
    Arq Bras Cardiol; 2005 Apr; 84(4):314-9. PubMed ID: 15880205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
    Wolffenbuttel BH; Mahla G; Muller D; Pentrup A; Black DM
    Neth J Med; 1998 Apr; 52(4):131-7. PubMed ID: 9646621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
    Simons LA
    Aust N Z J Med; 1998 Jun; 28(3):327-33. PubMed ID: 9673745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
    Roberts WC
    Am J Cardiol; 1997 Jul; 80(1):106-7. PubMed ID: 9205036
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.